Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480145 | PMC |
| http://dx.doi.org/10.1016/j.jbspin.2021.105282 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk of new onset of immune-mediated diseases after SARS-CoV-2 infection: A systematic review and meta-analysis.
Semin Arthritis Rheum
August 2025
Public Health Institute, Pontificia Universidad Javeriana, Bogotá, Colombia. Electronic address:
Objectives: The association between SARS-CoV-2 infection and new onset of immune-mediated diseases is of interest given the conflicting evidence. This study aims to gather evidence and estimate the risk of immune-mediated diseases following SARS-CoV-2 infection.
Methods: Analytical observational studies reporting immune-mediated diseases after confirmed SARS-CoV-2 infection, compared to individuals without infection history, were included.
Post spike syndrome (PSS): Simple solution leading to resolving results, five cases report.
IDCases
June 2025
Independent Researcher, Brazil.
Unlabelled: Post-Spike Syndrome (PSS) is an emerging condition associated with the Spike protein, originating from both SARS-CoV-2 infection and mRNA-based therapies. This case series explores the significant clinical impact of PSS, characterized By gut dysbiosis, systemic inflammation, and immune activation, leading to multisystem manifestations such as fatigue, brain fog, neuropathies, and reactivation of pre-existing diseases. A simple therapeutic approach was applied to five patients, resulting in notable symptom improvement.
View Article and Find Full Text PDFRisk of new-onset polymyalgia rheumatica following COVID-19 vaccination in South Korea: a self-controlled case-series study.
RMD Open
April 2025
Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Republic of Korea
Background: While several studies have reported some cases of polymyalgia rheumatica (PMR) following COVID-19 vaccination, studies using large databases are lacking.
Objectives: To investigate the risk of PMR after COVID-19 vaccination using self-controlled case series (SCCS) analysis METHODS: We used the National Health Insurance Database, linked with the COVID-19 registry between February 2021 and August 2023, to identify adults aged 50 years or older who received at least one dose of COVID-19 vaccine and subsequently diagnosed with PMR within the observation period, defined as 240 days after the first dose of vaccine. The risk window was defined as 28 days after each dose of COVID-19 vaccination, and the control window encompassed the remainder of the observation period.
Secondary Polymyalgia Rheumatica Following SARS-CoV-2 Infection.
Acta Med Okayama
December 2024
Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
An 81-year-old Japanese man with a medical history of diabetes mellitus and hypertension was diagnosed with the novel coronavirus disease 2019 (COVID-19). The patient developed pain in the bilateral shoulders and hips 3 days after the disease onset and presented to our outpatient clinic after 1 month. Referring to diagnostic criteria, we diagnosed him with polymyalgia rheumatica (PMR).
View Article and Find Full Text PDFPolymyalgia rheumatica following COVID-19 vaccination: Case series of 3 patients and literature review on polymyalgia rheumatica induced by various vaccines.
Medicine (Baltimore)
October 2024
Division of Rheumatology, Department of Internal Medicine, LAU Medical Center - Rizk Hospital, Zahar St., Achrafieh, Beirut, Lebanon.
Rationale: Since the onset of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic in 2019, considerable resources have been devoted to developing vaccines to reduce related deaths and the burden of disease. Various vaccine formulations eventually became available and were approved for clinical use. In this article, we have conducted a review of polymyalgia rheumatica (PMR) cases induced by different COVID-19 vaccines [Pfizer: BNT162b2, AstraZeneca: ChAdOx1-S, Moderna: mRNA-1273, and Janssen: Ad26.
View Article and Find Full Text PDF